<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04626609</url>
  </required_header>
  <id_info>
    <org_study_id>KLI 887-B</org_study_id>
    <nct_id>NCT04626609</nct_id>
  </id_info>
  <brief_title>Prostaglandin and Cannabinoid Receptors in EoE</brief_title>
  <official_title>Prostaglandin and Cannabinoid Receptors in the Development of Eosinophilic Esophagitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Graz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Graz</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate prostaglandin and cannabinoid receptors and their&#xD;
      endogenous ligands in eosinophilic esophagitis (EoE). A prostaglandin D2 receptor antagonist&#xD;
      has been shown to improve disease symptoms suggesting a regulatory role for bioactive lipids&#xD;
      in EoE. Prostaglandin D2 and E2, and endocannabinoids are lipid mediators that govern the&#xD;
      functional and inflammatory behavior of immune cells critical for EoE development. The&#xD;
      prostaglandin D2 and E2 receptor axis, and the components of the endocannabinoid may be&#xD;
      involved in the pathogenesis of EoE.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prostaglandin D2 and E2 receptors, and components of the endocannabinoid system (cannabinoid&#xD;
      receptors and endocannabinoid-metabolizing enzymes) are examined in mucosal esophageal&#xD;
      biopsies and blood leukocytes from EoE patients (acute and in remission), individuals with&#xD;
      gastroesophageal reflux and from individuals with no esophageal disease. Expression of these&#xD;
      components are compared between all cohorts by polymerase chain reaction, Western blots, flow&#xD;
      cytometry and immunohistochemical methods. EoE disease activity is evaluated by determining a&#xD;
      symptom score and the number of eosinophils per high-power field (hpf) in histologic sections&#xD;
      of mucosal biopsies. Additionally, an Endoscopic Reference Score (EREFS) is used. Disease&#xD;
      activity is correlated with cannabinoid/prostaglandin D2 and E2 receptor expression. Blood is&#xD;
      collected and immediately processed for flow cytometric experiments. Prostaglandins and&#xD;
      endocannabinoids are measured in plasma and esophageal mucosal biopsy samples of all cohorts&#xD;
      by mass spectrometry.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2021</start_date>
  <completion_date type="Anticipated">February 2025</completion_date>
  <primary_completion_date type="Anticipated">February 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Analysis of cannabinoid receptors- protein content</measure>
    <time_frame>within 48 months</time_frame>
    <description>Cannabinoid receptors (protein) are measured by flow cytometry in blood leukocytes of patients with EoE (acute and in remission), and of control individuals.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Analysis of cannabinoid receptors- transcripts</measure>
    <time_frame>within 48 months</time_frame>
    <description>Transcripts of cannabinoid receptors are measured in esophageal mucosal biopsies of patients with EoE (acute and in remission), GERD and in control individuals by polymerase chain reaction.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Analysis of prostaglandin D2 receptors- protein content</measure>
    <time_frame>within 48 months</time_frame>
    <description>Prostaglandin D2 receptors (protein) are measured by flow cytometry in blood leukocytes of patients with EoE (acute and in remission), and of control individuals.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Analysis of prostaglandin D2 receptors - transcripts</measure>
    <time_frame>within 48 months</time_frame>
    <description>Transcripts of prostaglandin D2 receptors are measured in esophageal mucosal biopsies of patients with EoE (acute and in remission), GERD and in control individuals by polymerase chain reaction.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Analysis of prostaglandin E2 receptors- protein content</measure>
    <time_frame>within 48 months</time_frame>
    <description>Prostaglandin E2 receptors (protein) are measured by flow cytometry in blood leukocytes of patients with EoE (acute and in remission), and of control individuals.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Analysis of prostaglandin E2 receptors- transcripts</measure>
    <time_frame>within 48 months</time_frame>
    <description>Transcripts of prostaglandin E2 receptors are measured in esophageal mucosal biopsies of patients with EoE (acute and in remission), GERD and in control individuals by polymerase chain reaction.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease activity Score</measure>
    <time_frame>within 48 months</time_frame>
    <description>Assessment of a Disease Activity Score:&#xD;
The Disease Activity Score will be assessed on the basis of the Gastroesophageal Reflux Disease-Health Related Quality of Life (GERD-HRQL) instrument (Velanovich V. Dis Esophagus. 2007;20 (2):130-4) and consists of a questionnaire rated from 0 to 5 where 0 indicates no symptoms while 5 indicates strong symptoms of heartburn and difficulties in swallowing that incapacitates to do daily activities.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endoscopic Reference Score</measure>
    <time_frame>within 48 months</time_frame>
    <description>Assessment of an Endoscopic Reference Score:&#xD;
Endoscopic findings will be assessed using the EoE Endoscopic Reference Score (EREFS) (Hirano et al. Gut. 2013; 62:489-495) which is composed of 5 classification categories. The classification features include edema, fixed rings, exsudates, furrows and stricture where grade 0 indicates the absence of the feature and grade 2 and 3 increasing severity of the feature.</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Eosinophilic Esophagitis (EoE)</condition>
  <arm_group>
    <arm_group_label>EoE group</arm_group_label>
    <description>Patients with confirmed eosinophilic esophagitis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GERD group</arm_group_label>
    <description>Patients with gastro-esophageal reï¬‚ux disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <description>Individuals with no esophageal disease</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Biopsy samples</intervention_name>
    <description>Esophageal mucosal biopsies are collected during gastroscopy</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>EoE group</arm_group_label>
    <arm_group_label>GERD group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood samples</intervention_name>
    <description>Blood will be drawn by venipuncture into citrate- or EDTA-containing vacutainer tubes and into serum tubes</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>EoE group</arm_group_label>
    <arm_group_label>GERD group</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood serum biopsies&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects undergoing gastroscopy at the outpatients clinic of the Medical University of Graz&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  diagnosed or suspected EoE or GERD&#xD;
&#xD;
          -  without esophageal diseases&#xD;
&#xD;
          -  with signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  viral or parasitic diseases (e.g. herpes, candidiasis)&#xD;
&#xD;
          -  eosinophilic gastroenteritis, hypereosinophilic syndrome, Crohn's disease&#xD;
&#xD;
          -  autoimmune diseases&#xD;
&#xD;
          -  unable to give informed consent&#xD;
&#xD;
          -  immunosuppressive therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rudolf Schicho, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Graz</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rudolf Schicho, PhD</last_name>
    <phone>+43316385</phone>
    <phone_ext>74132</phone_ext>
    <email>rudolf.schicho@medunigraz.at</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Franziska Durchschein, MD</last_name>
    <email>franziska.durchschein@medunigraz.at</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medical University of Graz</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Durchschein Franziska, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>November 6, 2020</study_first_submitted>
  <study_first_submitted_qc>November 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 12, 2020</study_first_posted>
  <last_update_submitted>August 31, 2021</last_update_submitted>
  <last_update_submitted_qc>August 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophagitis</mesh_term>
    <mesh_term>Eosinophilic Esophagitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

